Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC) Tuesday November 7th, 2017By Tokio X'press Cancer, FDA Opdivo Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients 20170911 Two important clinical trials Tuesday September 12th, 2017By Tokio X'press Cancer, JPN ONO Two important clinical trials
A ‘pen’ that can diagnose cancer in 10 seconds 2017/09/10 A ‘pen’ that can d Monday September 11th, 2017By Tokio X'press Cancer, USA University of Texas A ‘pen’ that can d
Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)